On September 29, 2026 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, hereafter "Chugai") and InxMed (Hong Kong) Limited (hereafter "InxMed") reported that they have entered into a worldwide license agreement regarding SPYK04, a RAF-MEK molecular glue discovered by Chugai for the treatment of solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, Chugai will grant InxMed an exclusive worldwide license to develop, manufacture, and commercialize SPYK04 for all indications. In return, Chugai will receive an upfront payment as well as royalties based on sales following product launch. In addition, in the event that InxMed receives income other than royalties from sublicensees, Chugai will be entitled to receive a certain portion of the income.
SPYK04 is a small-molecule compound discovered by Chugai for the treatment of solid tumors. Acting as a "molecular glue" that binds RAF and MEK, proteins involved in cancer cell proliferation, SPYK04 induces the formation of an inactive RAF-MEK complex, thereby inhibiting proliferative signaling in cancer cells, and is expected to exert antitumor effects.
Chugai’s President and CEO, Dr. Osamu Okuda, commented, "We are pleased to have entered into a license agreement for SPYK04 with InxMed, which has strong expertise in the oncology field. We expect that InxMed will steadily advance development leveraging the unique characteristics of SPYK04, and we hope that it will be delivered as a cancer treatment to patients around the world as soon as possible."
Dr. Zaiqi Wang, Founder, Chairman and CEO of InxMed, commented, "We are thrilled to enter into this licensing agreement with Chugai for asset SPYK04. This collaboration marks a significant milestone in our mission to deliver further precision oncology therapies. We look forward to rapidly advancing this asset to bring more effective, durable treatment options to cancer patients worldwide."
(Press release, Chugai, SEP 29, 2026, View Source [SID1234671143])